VRTX · 10-Q · 2026Q3 · Full report

Supply Chain Constraints

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 10 · Surprise 6

Vertex relies on a global network of third parties, including some in China, alongside internal capabilities to manufacture and distribute commercial products and clinical-trial candidates. It adapts supply chains for existing medicines to add formulations or increase production scale as needed, and establishes supply chains for newly approved products. Biological, cell, and genetic therapies require more complex processes and additional investment in systems, equipment, facilities, and expertise than small-molecule drugs. The company states that it is focused on maintaining stable supply chains for current products and pipeline programs; no specific constraint or lead-time disruption is reported.